



MASSACHUSETTS DEPARTMENT OF PUBLIC HEALTH
WEEKLY INFLUENZA UPDATE
March 2, 2018

All data in this report are preliminary and subject to change as more information is received.


Sentinel Provider Surveillance: Influenza-like illness activity

Week 8 Activity¹ (representing geographic distribution): Widespread

Week 8 ILI Activity² (representing intensity of ILI activity): 10 (High)

Provider offices across the US report the amount of influenza-like illness (ILI) they see in their patients each week during regular flu season. These outpatient providers' offices, which include doctors' offices, school health services, and community health centers, are called 'sentinel sites.' Here we present Massachusetts sentinel site data. Please note that the data represent not only confirmed influenza cases, but also those just with ILI, which may be caused by other viruses. ILI is defined as fever above 100.0¹ in addition to either cough or sore throat. ILI is a marker of influenza and is used throughout the regular influenza season to monitor influenza since most people are not tested for influenza. Figure 1 shows that influenza-like illness activity remains elevated, consistent with activity in other parts of the United States. For more information, see CDC's influenza surveillance website at www.cdc.gov/flu/weekly/fluactivitysurv.htm.

Figure 1: Percentage of ILI visits reported by sentinel provider sites




*Influenza-like illness (ILI, defined by fever >100F and cough and/or sore throat), as reported by Massachusetts sentinel surveillance sites

¹ CDC activity indicator – indicates how widespread influenza activity level is in the state.

² CDC ILI activity indicator – more quantitative indicator of the level of ILI activity across the state.

Figure 2 shows the intensity of reported ILI activity in Massachusetts by region. The activity level for each region (and associated color) is in relation to a baseline ILI activity level for that region. Differences in activity may reflect variation in the size and type of patient population served by reporting providers in that region. Figure 2 shows that all regions of the state are reporting increased ILI activity.

Figure 2: Percent ILI Activity Level Reported Weekly by Massachusetts Sentinel Sites




Laboratory testing for influenza

Laboratories in Massachusetts report all positive influenza laboratory tests to MDPH, including viral culture, polymerase chain reaction (PCR) and rapid influenza diagnostic tests. Because the majority of cases are not tested, the number of 'confirmed' cases does not reflect the overall incidence of influenza; however, this information is essential to track the types of influenza circulating in Massachusetts and can be a useful indicator of the presence and distribution of influenza in the state. Table 1 reflects the number of influenza cases confirmed via viral culture or PCR test by region and influenza type. Figure 3 illustrates the number of laboratory confirmed cases in Massachusetts by week, shown along with Massachusetts ILI.

Table 1: Laboratory-confirmed Influenza by Region – 2017-2018 and 2016-2017 Influenza Seasons

Region	2017-2018						2016-2017					
	A		B		Untyped		A		B		Untyped	
	Week	YTD	Week	YTD	Week	YTD	Week	YTD	Week	YTD	Week	YTD
Boston	148	1,537	53	393	0	0	131	858	15	78	0	0
Central	47	525	31	214	0	0	47	258	5	16	0	0
Inner Metro Boston	143	1,362	68	382	0	0	56	413	10	24	0	0
Northeast	348	2,834	227	1,452	0	0	105	617	26	97	0	0
Outer Metro Boston	55	552	30	208	0	0	55	282	7	36	0	0
Southeast	68	740	21	142	0	0	21	151	7	18	0	0
Unknown	13	142	5	37	0	0	12	98	2	7	0	0
West	420	4,121	195	1,130	0	0	214	1,842	44	108	0	0
Total	1,242	11,813	630	3,958	0	0	641	4,519	116	384	0	0

**Figure 3: Laboratory-confirmed Influenza Cases and Influenza-like Illness
Massachusetts, October 1, 2017 – February 24, 2018**




*Influenza cases confirmed via viral culture or PCR test by specimen collection date.

**Influenza-like illness (ILI, defined as fever >100F and cough and/or sore throat), as reported by Massachusetts sentinel surveillance sites by CDC week date.

Influenza-Associated Hospitalizations

In 2010, MDPH began to request voluntary reporting of all laboratory-confirmed influenza hospitalizations from hospitals in Massachusetts. As many as 50 acute care hospitals from across the state report these data to MDPH on a weekly basis during flu season. The graph below shows the number of laboratory-confirmed hospitalizations per 1,000 licensed beds represented by reporting hospitals for the current season and two previous seasons.

Figure 4: Massachusetts laboratory-confirmed influenza hospitalizations



Testing at the State Public Health Laboratory

As part of a more comprehensive respiratory surveillance initiative, MDPH’s Bureau of Infectious Disease and Laboratory Sciences (MDPH-BIDLS) performs testing to confirm typing and subtyping of circulating influenza viruses followed by testing of influenza-negative samples for the evidence of adenovirus, respiratory syncytial virus (RSV) A/B, parainfluenza virus (PIV) types 1-4 , coronavirus (HCoV) HKU1, OC43, NL63, 229E, human metapneumovirus (HMPV), and rhinovirus/enterovirus (RHV/ENT) using a multiplex PCR respiratory viral panel. Samples are submitted by ~60 outpatient healthcare providers (ILINet) and include early influenza positives, as well as specimens and isolates from clinical hospital diagnostic laboratories across Massachusetts. For the 2017-2018 season, Figure 5 and Tables 2 and 3 summarize virologic surveillance testing conducted by MDPH-BIDLS beginning MMWR week 40 (week ending October 7, 2017). MDPH-BIDLS performs influenza surveillance testing year round. For the 2017-2018 season to date, 138 cases of A/H3N2 influenza, 22 cases of A/2009 H1N1, 62 cases of B/Yamagata, and 15 cases of B/Victoria have been confirmed in 439 cases tested.

Figure 5: Influenza positive tests reported to CDC by MDPH-BIDLS, October 1, 2017 – February 24, 2018




Table 2: Weekly Summary of MDPH-BIDLS Influenza Surveillance Test Results

2017-2018 Season: Influenza Surveillance									
MA Department of Public Health’s Bureau of Infectious Disease and Laboratory Sciences (MDPH-BIDLS)									
MMWR Week: (Specimen Collected)	2009 H1N1	seasonal A/H3N2	H3N2v	B Yam	B Vic	No. Flu Pos (%)	Unsat	Total Tested	Total Rec’d
05 (01/28 - 02/03/2018)	4	41	0	8	3	56(63%)	2	89	91
06 (02/04 - 02/10/2018)	4	16	0	10	2	32(54%)	2	59	61
07 (02/11 - 02/17/2018)	3	11	0	12	5	31(63%)	7	49	56
08 (02/18 - 02/24/2018)	3	12	0	9	5	29(71%)	1	41	42
Prior 4 wk Total	14	80	0	39	15	148(62%)	12	238	250
Cumulative Season total	22	138	0	62	15	237(54%)	35	439	474

All data are subject to change as test results become finalized. The 2017 -2018 influenza season began MMWR 40 (10/01- 10/07/2017).

Table 3: Weekly Summary of MDPH-BIDLS non-Influenza Respiratory Surveillance Test Results


2017-2018 Season: Influenza Like Illness Surveillance											
MA Department of Public Health's Bureau of Infectious Disease and Laboratory Sciences (MDPH-BIDLS)											
MMWR Week: (Specimen Collected)	RSV	RHV/ ENT	PIV	HMPV	HCV	ADV	# Co- Infection	No. Pos (%)	Unsat	Total Tested	Total Rec'd
05 (01/28 – 02/03/2018)	2	3	0	0	5	1	1	10(36%)	0	28	28
06 (02/04 – 02/10/2018)	7	2	0	0	5	0	3	11(44%)	0	25	25
07 (02/11 – 02/17/2018)	1	0	1	2	3	1	0	8(50%)	0	16	16
08 (02/18 – 02/24/2018)	0	1	0	0	1	1	0	3(25%)	0	12	12
Prior 4 wk Total	10	6	1	2	14	3	4	32(40%)	0	81	81
Cumulative Season total	23	23	3	4	30	5	7	81(43%)	0	188	188

All data are subject to change as test results become finalized. The 2017-2018 influenza season began MMWR 40 (10/01- 10/07/2017).

For the 2017-2018 season, two original specimens positive for each influenza virus A(H3N2), influenza virus A(H1N1)pdm09, and influenza virus B (with one sample from each Victoria and Yamagata lineage, if possible) will be sent every two weeks by MDPH-BIDLS to a CDC contract laboratory performing National Influenza Virus Surveillance standardized test methods. Antigenic characterization of these submitted specimens include: hemagglutination inhibition (HI), genetic analysis (sequencing) and sensitivity to FDA-approved drugs for identification of resistance. Selection criteria for submitting influenza positive specimens will be based on a Ct value (<30) for Inf A and Inf B tests using the CDC Flu rRT-PCR Dx Panel. See Figure 6 for a summary of specimens characterized in the 2017-2018 season to date.

Figure 6: Summary of 2017-2018 CDC Contract Laboratory Specimen Characterization

INFLUENZA VIRUS TYPE	CHARACTERIZED TOTAL
A/HONG KONG/4801/2014-LIKE	1
B/PHUKET/3073/2013-LIKE	1
A/MICHIGAN/45/2015-LIKE	1



The CDC Flu rRT-PCT Dx Panel for Influenza A subtyping was updated prior to the start of the 2016-2017 season. The oligonucleotide primers and probe were improved to ensure detection of currently circulating influenza A(H1N1)pdm09 viruses. The “seasonal” H1 target from Influenza A(H1N1) viruses that caused seasonal epidemics in humans prior to 2009 no longer circulates in humans and this target within the assay was discontinued.

As samples are received, MDPH-BIDLS will screen additional samples every two weeks to detect point mutations within the neuraminidase gene of influenza A/H3N2 viruses (E119, R292, and N294) and influenza A/2009 H1N1 viruses (H275 and I223) to assess resistance trends using the current CDC pyrosequencing method. This information will be reported locally and captured nationally in FluView (<http://www.cdc.gov/flu/weekly/>). For the 2015-2016 season, one A/2009 H1N1 isolate with a mutation conferring oseltamivir-resistance (H275H/Y) was detected. No mutations were detected in the 2016-2017 season.

Table 4: DPH-BIDLS Influenza Antiviral Resistance Screening: 2017-2018 Season

Virus Collection Period: October 1, 2017- ongoing				
	Oseltamivir		Zanamivir	
	Samples Tested	Resistant Viruses, Number (%)	Samples Tested	Resistant Viruses, Number (%)
Influenza A (H3N2) ⁱ	74	1 (1%)	74	0 (0)
Influenza A (H1N1)pdm09 ⁱⁱ	10	0 (0)	0	0 (0)

ⁱ Samples tested by pyrosequencing at position E119, R292, and N294 within the neuraminidase (NA) gene.

ⁱⁱ Samples tested by pyrosequencing at position H275 and I223 within the NA gene.

Additional information on national antiviral resistance testing including recommendations for antiviral treatment and chemoprophylaxis of influenza virus infection can be found at <http://www.cdc.gov/flu/weekly/>.